One of the long-running catalysts for small- and mid-sized biotechnology companies is the possibility that they’ll eventually be acquired by large-cap brethren or blue-chip pharmaceutical firms. While the biotech industry’s history of mergers and acquisitions is extensive, deal-making in the space has been sluggish over the past couple of years, frustrating investors in the process. [...] The post Biotech M&A Could Finally Be Ready to Rebound appeared first on ETF Trends .